Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

U.S. National Institutes Of Health, India's Cadila Healthcare Join Forces To Develop A New HPV Vaccine

This article was originally published in PharmAsia News

Executive Summary

SINGAPORE - India's Zydus Cadila has joined hands with the U.S.-based National Institutes of Health to develop a new prophylactic vaccine against human papilloma virus - known to be a major cause of cervical cancer

You may also be interested in...



Sanofi Beats GSK To Buy Merieux Alliance's Stake In India's Shantha Biotech; Move Aimed At Stronger Vaccines Business In Emerging Markets

MUMBAI - In a takeover battle that lasted several months, drug maker Sanofi-Aventis emerged winner beating global rival GlaxoSmithKline among others to lap up a majority equity stake in India's Shantha Biotechnics from fellow French pharmaceutical firm Merieux Alliance. Shantha Biotechnics was valued at €550 million ($750 million) on expected sales of €90 million for the current financial year

Merck Launches Gardasil In India At Half U.S. Price

MUMBAI - Merck's India affiliate MSD Pharmaceuticals has launched blockbuster cervical cancer vaccine Gardasil in India at $170 (Rs 8,400) per three-dose regimen, nearly half of its U.S. price of $350

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

UsernamePublicRestriction

Register

SC074339

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel